Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopure’s Hemopure BPAC Review To Be Closed-Door

This article was originally published in The Pink Sheet Daily

Executive Summary

The day before Biopure's July 14 review, FDA's Blood Products Advisory Committee will discuss Nabi's Nabi-HB immunoglobulin for hepatitis B.

You may also be interested in...



FDA Closed-Door Hemopure Meeting Violates Advisory Committee Act, Cries Wolfe

Public Citizen is seeking a temporary restraining order against FDA’s Blood Products Advisory Committee closed-door review of Biopure’s oxygen therapeutic.

FDA Closed-Door Hemopure Meeting Violates Advisory Committee Act, Cries Wolfe

Public Citizen is seeking a temporary restraining order against FDA’s Blood Products Advisory Committee closed-door review of Biopure’s oxygen therapeutic.

Biopure Submits Hemopure Application In The U.K.

The company says it targeted the United Kingdom before the rest of the EU because of the country's "unique blood banking issues."

Related Content

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel